Sandoz v. Duke University & Allergan: Federal Circuit Reverses on Written Description
Sandoz, Inc. challenged the validity of US9579270B2, a Duke University patent covering non-naturally occurring prostaglandin compositions for hair loss treatment, licensed to Allergan Sales. After 755 days, the Federal Circuit reversed the district court, holding that no reasonable factfinder could have found anything other than clear and convincing evidence that claim 30 lacks adequate written description.
Federal Circuit Invalidates Allergan Prostaglandin Hair Loss Patent Claim
Sandoz, Inc. filed appeal No. 24-1078 at the Court of Appeals for the Federal Circuit on October 25, 2023, challenging a district court judgment that had upheld claim 30 of US9579270B2. That patent, assigned to Duke University and exclusively licensed to Allergan Sales, LLC, covers compositions and methods for treating hair loss using non-naturally occurring prostaglandins — a technology directly relevant to ophthalmic and dermatological drug markets.
On November 18, 2025, the Federal Circuit reversed the district court. The court applied the clear-and-convincing evidence standard and concluded that no reasonable factfinder, viewing the evidence in the light most favorable to Allergan, could have reached any conclusion other than that claim 30 is invalid for lack of adequate written description under 35 U.S.C. § 112. The reversal extinguishes Allergan’s ability to enforce claim 30 against Sandoz in this proceeding.
The 755-day appellate duration is consistent with a technically complex written description dispute requiring detailed review of the original patent specification. The Federal Circuit’s ‘no reasonable factfinder’ framing suggests the written description deficiency was considered clear-cut on the record, rather than a close call. What remains unknown from the public record is whether additional claims of the patent were separately challenged, and whether Allergan intends to seek further review.
Filing to Case Reversed in 755 days
755 days from filing to Federal Circuit decision — consistent with a contested appellate proceeding following district court trial
Federal Circuit reverses: what the ruling means for both parties
What ‘REVERSED’ means at the Federal Circuit level
A reversal by the Federal Circuit means the appellate court found that the district court committed a reversible legal error — here, by allowing claim 30 to survive validity challenge. The Federal Circuit applied a JMOL-equivalent standard, concluding that no reasonable factfinder could have found insufficient evidence of invalidity. The district court’s judgment is displaced; claim 30 is now held invalid as a matter of law.
District court judgment displacedSandoz wins: invalidity established, claim 30 falls
Sandoz prevailed on appeal. The Federal Circuit’s reversal means claim 30 of US9579270B2 is invalid for lack of adequate written description, removing the primary legal basis Allergan held for asserting this claim against Sandoz. This outcome clears a significant patent obstacle for Sandoz’s prostaglandin-related product activities and may benefit other generic or biosimilar competitors facing the same claim.
Invalidity confirmed on appealAllergan loses enforceability of claim 30 after appeal
Duke University and Allergan Sales, LLC are the losing parties at this appellate stage. Allergan’s remaining written description arguments were expressly found unpersuasive by the court. With the Federal Circuit acting as the court of last resort for patent law, options for further challenge are limited to a petition for en banc rehearing or a certiorari petition to the Supreme Court — both of which face high procedural bars.
Claim 30 unenforceableProstaglandin hair loss IP landscape shifts after reversal
The invalidation of claim 30 of US9579270B2 suggests that overly broad claims in prostaglandin hair loss patents face real written description vulnerability at the Federal Circuit. Generic and specialty pharma companies developing non-naturally occurring prostaglandin formulations for hair loss should assess remaining claims in the patent family. The ruling may also embolden invalidity challenges to related claims in adjacent dermatological and ophthalmic drug patents.
Generic competition risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Sandoz, Inc. | Company | Generic pharmaceutical company — challenger of US9579270B2 prostaglandin hair loss patentSearch in Eureka ↗ |
| Defendant | Duke University | Individual | Duke University (patent holder) and Allergan Sales, LLC (licensee and enforcement party)Search in Eureka ↗ |
| Co-Defendant | Allergan Sales, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Gabriel Ferrante | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert Kappers | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Vishal C. Gupta | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William M. Jay | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Goodwin Procter LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Steptoe, LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth Kathleen Clarke | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Hassen A. Sayeed | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Jeffrey A. Lamken | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Kayvon Ghayoumi | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Lisa Barons Pensabene | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Michael Gregory Pattillo | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Sara Margolis | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Defendant law firm | MoloLamken LLP | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Defendant law firm | O’Melveny & Myers LLP | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s verdict language is notably unequivocal: the court found that ‘no reasonable factfinder, taking the evidence in the light most favorable to Allergan,’ could have concluded otherwise than that claim 30 lacks adequate written description by clear and convincing evidence. This phrasing invokes JMOL-equivalent reasoning at the appellate level, indicating that the written description deficiency was so clear on the record that the district court’s contrary judgment could not stand. The appellate standard applied — deferential to district court findings of fact but de novo on questions of law — was effectively bypassed by the strength of the invalidity evidence, leaving Allergan with limited grounds for further review.
US9579270B2 — Prostaglandin Compositions for Hair Loss Treatment
US9579270B2, filed under application number US14/958334, protects compositions and methods for treating hair loss using non-naturally occurring prostaglandins. Prostaglandin analogues have established clinical relevance in ophthalmic drug development — notably in glaucoma treatments that also demonstrated hair growth side effects — making this patent strategically positioned at the intersection of dermatology and ophthalmology. The patent is assigned to Duke University, reflecting academic research origins, and was exclusively licensed to Allergan Sales, LLC for commercial exploitation.
This patent sits within a competitive technology space where prostaglandin analogues are actively developed by both branded and generic pharmaceutical companies. Allergan’s broader prostaglandin portfolio has significant commercial value in dermatological and ophthalmic applications. The Federal Circuit’s invalidation of claim 30 for written description deficiency suggests the claim scope extended beyond what the original specification adequately disclosed — a recurring vulnerability in patents drafted around newly discovered biological mechanisms. Competitors and ANDA filers should treat this ruling as a signal to map the full patent family before product launch decisions.
Should your pipeline trigger an FTO against US9579270B2?
Any company developing, manufacturing, or commercialising non-naturally occurring prostaglandin formulations for hair loss, scalp conditions, or adjacent dermatological indications should treat US9579270B2 as a live FTO concern. While claim 30 has been judicially invalidated, the patent may contain additional claims with different scope. ANDA filers, 505(b)(2) applicants, and specialty pharma product teams should not assume the reversal on claim 30 clears the entire patent — claim-level analysis is essential before launch.
PatSnap Eureka’s FTO Search Agent enables rapid claim-level mapping of US9579270B2 against your product specification. The tool identifies which remaining claims may read on your compound or method, surfaces prior art relevant to § 112 or § 102 challenges, and flags related patents in the Duke/Allergan prostaglandin family. For BD and legal teams assessing portfolio risk or licensing terms in the wake of this Federal Circuit decision, Eureka provides structured, auditable FTO outputs ready for counsel review.
Run a freedom-to-operate analysis on US9579270B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Appeals: Pharmaceutical Written Description Disputes
Cases at the Federal Circuit involving written description invalidity challenges to pharmaceutical composition patents, including prostaglandin and small-molecule drug claims.
What this case signals for the prostaglandin drug patent IP landscape
The Federal Circuit’s reversal in Sandoz v. Duke/Allergan reshapes the enforceability calculus for prostaglandin-based pharmaceutical patents.
Written description is a high-risk vulnerability for broad pharma claims
The Federal Circuit’s conclusion that invalidity was established as a matter of law — not just by the preponderance standard — signals rigorous scrutiny of written description in pharmaceutical patents. Companies holding broad prostaglandin or analogous compound claims should audit whether their original specifications adequately support the full claim scope, particularly for non-naturally occurring compounds.
Generic challengers gain a validated appellate pathway for § 112 attacks
Sandoz’s success demonstrates that written description challenges can succeed even after district court loss. For generic and biosimilar entrants facing prostaglandin hair loss or ophthalmic drug patents, this ruling provides both a legal precedent and a tactical model: a well-developed § 112 record at trial can support a strong reversal argument at the Federal Circuit.
Sandoz v Duke — key questions answered
The Federal Circuit reversed the district court, holding that claim 30 of US9579270B2 is invalid for lack of adequate written description. The court concluded that no reasonable factfinder, viewing evidence in Allergan’s favour, could have found anything other than clear and convincing evidence of invalidity under 35 U.S.C. § 112.
US9579270B2 is a patent assigned to Duke University covering compositions and methods for treating hair loss using non-naturally occurring prostaglandins. It was exclusively licensed to Allergan Sales, LLC. The patent sits at the intersection of dermatology and ophthalmology, reflecting research into prostaglandin analogues with hair growth effects.
Claim 30 of US9579270B2 is now invalid and cannot be enforced by Allergan against Sandoz or, effectively, any third party. Allergan’s remaining enforcement options depend on other claims in the same patent and related patents in the prostaglandin hair loss family. The ruling does not automatically invalidate the entire patent.
The invalidation of claim 30 removes one enforcement tool Allergan held against generic competition. ANDA filers and 505(b)(2) applicants developing prostaglandin hair loss products should conduct a claim-level FTO review of US9579270B2 to assess which, if any, remaining claims could still present infringement risk, and whether the written description precedent assists in challenging those claims.
Following a Federal Circuit reversal, the losing parties may petition for en banc rehearing before the full Federal Circuit or seek certiorari from the U.S. Supreme Court. Both paths face high procedural thresholds. The public record does not indicate whether Allergan or Duke University has pursued or intends to pursue either option following the November 2025 decision.
PatSnap Eureka searches patents and litigation data to answer instantly.